Cathie Wood’s ARK sees major activity in CoreWeave and Personal Genome stock
ARK ETFs made significant trades on October 14, 2026, including buying 188,665 shares of CoreWeave (CRWV) for $14.7M and selling 693,049 shares of Personal Genome (PSNL) for $11M. Other notable transactions involved Meta (META), 10X Genomics (TXG), Toast (TOST), and Cerebras (CBRS).
How this was made
The 30-second read
Why it matters
The disclosed buys and sells can influence short‑term price dynamics, especially for smaller caps where ARK's trades represent a notable ownership percentage.
Market read
Fund flow news is a modest catalyst; larger impact expected for smaller‑cap stocks with sizable ARK positions.
What to watch
The trades may reflect internal portfolio rebalancing rather than fundamental changes in the companies.
Background
ARK's daily trade disclosures provide insight into its evolving portfolio allocations across technology and healthcare.
Ticker impact
ARK purchased 188,665 shares of CoreWeave, indicating fresh buying interest.
likely upward pressure as market prices in ARK's accumulation
Large disclosed purchase suggests confidence in growth prospects.
ARK sold 693,049 shares of Personal Genome Diagnostics, reducing its stake.
potential short‑term downside as investors note the divestiture
Significant share reduction may signal concerns about the company's outlook.
ARK bought 9,577 shares of Meta Platforms, adding to its position.
slight upward bias as the trade reflects confidence
Purchase size is modest relative to market cap but indicates continued interest.
ARK sold 113,555 shares of 10X Genomics, trimming its holding.
downward pressure as the market absorbs the sell signal
Large sell from a well‑known fund can weigh on sentiment.
ARK sold 337,473 shares of Toast, decreasing exposure.
potential short‑term dip
Sizeable sell may prompt traders to reassess Toast's outlook.
ARK bought 44,689 shares of Cerebras Systems, adding to its position.
upward bias as market sees confidence in AI demand
Purchase aligns with ARK's focus on disruptive tech.
ARK sold 31,432 shares of Palantir Technologies, reducing its stake.
downward pressure in the near term
Even a modest sell from ARK can affect sentiment for a high‑profile name.
ARK bought 110,037 shares of Freenome, increasing its holding.
slight upside as market notes new backing
Small purchase relative to market cap limits impact.
Market effects
Highlights ARK's tilt toward cloud, AI, and biotech, possibly nudging sector sentiment.
U.S. equity market, with modest influence on tech and healthcare subsectors.
Limited to investors tracking active‑manager flows; no broad macro effect.
Counterpoint
Some may view ARK's sells as a warning sign for the genomics space despite overall sector optimism.
Key entities
- PersonCathie Wood
Founder of ARK Invest, whose fund actions drive market attention.
- FirmARK Invest
Active manager known for thematic investing in disruptive technologies.
